ArticleAntimicrobial agents and chemotherapy2018
Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Antimicrobial peptides for tuberculosis in a post-antibiotic era: from in vitro promise to therapeutic potential.npj antimicrobials and resistance · 2026Review
- Review
- Peptide-Based Strategies AgainstPharmaceuticals (Basel, Switzerland) · 2025Review
- Bacteriocins: potentials and prospects in health and agrifood systems.Archives of microbiology · 2024Review
- Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.Current topics in medicinal chemistry · 2024Review
- Immunomodulation, Bioavailability and Safety of Bacteriocins.Life (Basel, Switzerland) · 2023Review
- ApoE Mimetic Peptide COG1410 Exhibits Strong Additive Interaction with Antibiotics AgainstInfection and drug resistance · 2023Article
- Review
- Advances in the preclinical characterization of the antimicrobial peptide AS-48.Frontiers in microbiology · 2023Review
- Embedding Biomimetic Magnetic Nanoparticles Coupled with Peptide AS-48 into PLGA to Treat Intracellular Pathogens.Pharmaceutics · 2022Article
- Combined Action of Antibiotics and Bacteriocins against Vancomycin-Resistant Enterococci.Microorganisms · 2022Article
- The Role of Key Amino Acids in the Antimicrobial Mechanism of a Bacteriocin Model Revealed by Molecular Simulations.Journal of chemical information and modeling · 2021Article
- Applications of Lysozyme, an Innate Immune Defense Factor, as an Alternative Antibiotic.Antibiotics (Basel, Switzerland) · 2021Review
- Evolution of Antibacterial Drug Screening Methods: Current Prospects for Mycobacteria.Microorganisms · 2021Review
- Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.Microorganisms · 2021Review
- Selective Targeting of Human and Animal Pathogens of theInternational journal of molecular sciences · 2021Article
- Antimicrobial Activity of the Circular Bacteriocin AS-48 against Clinical Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Experimental elucidation of an antimycobacterial bacteriocin produced by ethnomedicinal plant-derived Bacillus subtilis (MK733983).Archives of microbiology · 2021Article
- Microbiome-immune interactions in tuberculosis.PLoS pathogens · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing incidence of multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.